AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01468740
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
Trial: NCT00624312
Drug: Procrit
RxNorm normalized name: Procrit
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit
Trial: NCT00021749
Drug: Oblimerson sodium, G3139
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00988078
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500mg three times a day for six months
Trial: NCT00161018
Drug: Quetiapine, Risperidone, Fluphenazine
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02560519
Drug: Albumin solution
RxNorm normalized name: darbepoetin alfa in albumin solution
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.~During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy.The volume replacement therapy is not determined but will be based on the clinical decision.
Trial: NCT02560519
Drug: Ringers acetate solution
RxNorm normalized name: Mimulus ringens whole extract
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.~During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not determined but will be based on the clinical decision.
Trial: NCT03709719
Drug: Blinatumomab Injection
RxNorm normalized name: blinatumomab Injection
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blinatumomab 28 μg/day : D1 to D28
Trial: NCT00530842
Drug: Tiotropium plus Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00530842
Drug: Fluticasone/Salmeterol
RxNorm normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01649635
Drug: CABAZITAXEL (XRP6258)
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution Route of administration: intravenous
Trial: NCT01649635
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet Route of administration: oral
Trial: NCT01649635
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet Route of administration: oral
Trial: NCT01649635
Drug: G-CSF (Granulocyte colony-stimulating factor)
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Trial: NCT00922207
Drug: Adefovir
RxNorm normalized name: Adefovir
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From week -4 to week 2
Trial: NCT00922207
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: From week -4 to week 2
Trial: NCT00922207
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 micrograms sc weekly, from week 1-48
Trial: NCT02311907
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV, over 30 minutes per planned chemotherapy regimen
Trial: NCT02311907
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV, over 1 or 3 hours, per planned chemotherapy regimen
Trial: NCT02631551
Drug: GSP 301 NS
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
Trial: NCT02631551
Drug: Olopatadine HCl NS
RxNorm normalized name: NS-2359
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 sprays in each nostril twice daily for 14 days
Trial: NCT00920725
Drug: Insulin (Aspart Insulin [Novolog], Regular Insulin)
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous
Trial: NCT01490112
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
Trial: NCT02631551
Drug: Mometasone furoate NS
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 sprays in each nostril twice daily for 14 days
Trial: NCT02631551
Drug: GSP 301 Placebo NS
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sprays in each nostril twice daily for 14 days
Trial: NCT00491517
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
Trial: NCT00217932
Drug: Divalproex Sodium (Depakote)
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00462007
Drug: Stalevo
RxNorm normalized name: Stalevo
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 3-4 daily doses for 6 weeks
Trial: NCT02444949
Drug: endostar
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02444949
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01367834
Drug: somatotropin
RxNorm normalized name: Somatotropin
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
Trial: NCT02068430
Drug: Riboflavin 0.1%
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
Trial: NCT03686904
Drug: Benzalkonium Gel
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiofilm solution (BlastX) topical wound gel
Trial: NCT03686904
Drug: benzalkonium irrigation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: washing and lavaging in clinic with benzalkonium irrigation
Trial: NCT00870181
Drug: systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01553721
Drug: udenafil
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)
Trial: NCT01785004
Drug: omega-3 fatty acids (fish oil)
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01312441
Drug: Ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergocalciferol capsules 50,000 IU once weekly for 6 months
Trial: NCT00000526
Drug: encainide
RxNorm normalized name: Encainide
DrugBank: Encainide (DB01228)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000526
Drug: flecainide
RxNorm normalized name: Flecainide
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000526
Drug: moricizine
RxNorm normalized name: Moricizine
DrugBank: Moricizine (DB00680)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00166166
Drug: Tetraethylammonium (TEA)
RxNorm normalized name: tetraethylammonium hydroxide
DrugBank: Tetraethylammonium (DB08837)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
Trial: NCT00166166
Drug: L-NG-monomethyl Arginine (L-NMMA)
RxNorm normalized name: L-Ng-monomethyl Arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 minute intra-arterial infusion of L-NMMA 8 μmol/min
Trial: NCT00166166
Drug: Bradykinin
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
Trial: NCT00166166
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
Trial: NCT00166166
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
Trial: NCT00166166
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
Trial: NCT03699293
Drug: Aspirin 81mg tablet
RxNorm normalized name: Sunmark Low Dose Aspirin 81mg Tablet
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
Trial: NCT02354885
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coagulation Management / Efficiency
Trial: NCT01269853
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental portion of this proposal:~This trial will have two experimental arms that will be open labeled and non-randomized.~ARM 1 (If the patient has multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.~Repeat Cycle
Trial: NCT01269853
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment~If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle
Trial: NCT04706949
Drug: Pyrotinib combined with pemetrexed plus carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Pyrotinib: oral administration within 30 minutes after breakfast, 400mg / day, continuous administration for 21 days as a cycle; each continuous pause time and the cumulative pause time of each cycle should not exceed 14 days. It is allowed to suspend the drug for many times due to adverse events.~2. Pemetrexed: the recommended dosage is 500mg / m2, once every three weeks. 3) Carboplatin: the dosage was determined according to Calvert formula, in which AUC was 5mg / ml / min.
Trial: NCT04191486
Drug: T-817MA
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.
Trial: NCT02794766
Drug: Inulin+SS
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
Trial: NCT02794766
Drug: S salivarius
RxNorm normalized name: Lactobacillus Salivarius
DrugBank: Lactobacillus salivarius (DB16544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
Trial: NCT00647530
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00036036
Drug: CP-461
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00793754
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg / day for 8 weeks
Trial: NCT00793754
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg / day for 8 weeks
Trial: NCT00793754
Drug: Aspirin + Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
Trial: NCT03035045
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01176058
Drug: Anidulafungin/Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
Trial: NCT01533519
Drug: Neuropeptide Y
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal administration will be administered with a nasal drug delivery device.
Trial: NCT00659074
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ODT, single-dose, fasting
Trial: NCT00659074
Drug: Zofran
RxNorm normalized name: Zofran
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ODT, single-dose, fasting
Trial: NCT00940901
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)
Trial: NCT02296567
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
Trial: NCT02296567
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
Trial: NCT02296567
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
Trial: NCT02296567
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
Trial: NCT02296567
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
Trial: NCT02296567
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
Trial: NCT02296567
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
Trial: NCT02168907
Drug: 6,8-bis(benzylthio)octanoic acid
RxNorm normalized name: 6,8-bis(benzylthio)octanoic acid
DrugBank: Devimistat (DB12109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02431663
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration in continuous
Trial: NCT00234091
Drug: Abacavir
RxNorm normalized name: Abacavir
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 8 mg/kg (up to 300 mg/dose) take orally twice daily
Trial: NCT00234091
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 to 600 mg taken orally once daily
Trial: NCT00234091
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mg/kg (up to 150 mg/dose) taken orally twice daily
Trial: NCT00234091
Drug: Lopinavir/Ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 230 mg/57.5 mg/m\^2 body surface area taken orally twice daily with food
Trial: NCT00234091
Drug: Nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45-55 mg/kg taken orally twice daily with food
Trial: NCT00234091
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120 mg/m\^2 once daily for first 14 days, tehn 200 mg/m\^2 (up to 400 mg/day) twice daily
Trial: NCT00234091
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180-240 mg/m\^2 every 12 hours (up to 300 mg/dose)
Trial: NCT00320294
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00320294
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00270803
Drug: Tetra Hydro Cannabinol (THC)
RxNorm normalized name: Cannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral THC 13mg and 17mg smoked in low nicotine cigarettes
Trial: NCT02168907
Drug: bendamustine hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01177852
Drug: diphenhydramine + dropropizine + pseudoephedrine
RxNorm normalized name: diphenhydramine / pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml
Trial: NCT01177852
Drug: Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).
DrugBank: Brompheniramine (DB00835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml
Trial: NCT00333060
Drug: OT-551 ophthalmic solution
RxNorm normalized name: OT-551
DrugBank: OT-551 (DB05650)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00684996
Drug: etaracizumab
RxNorm normalized name: Etaracizumab
DrugBank: Etaracizumab (DB12213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV